{"protocolSection":{"identificationModule":{"nctId":"NCT00191191","orgStudyIdInfo":{"id":"5250"},"secondaryIdInfos":[{"id":"H3E-JE-NS01","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)","officialTitle":"LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial"},"statusModule":{"statusVerifiedDate":"2009-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-10"},"primaryCompletionDateStruct":{"date":"2008-10","type":"ACTUAL"},"completionDateStruct":{"date":"2008-10","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-12","studyFirstSubmitQcDate":"2005-09-12","studyFirstPostDateStruct":{"date":"2005-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-10-23","resultsFirstSubmitQcDate":"2009-10-23","resultsFirstPostDateStruct":{"date":"2009-11-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-12-04","lastUpdatePostDateStruct":{"date":"2009-12-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":226,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed 500 mg/m2","type":"EXPERIMENTAL","description":"Pemetrexed 500 mg/m2","interventionNames":["Drug: Pemetrexed 500 mg/m2"]},{"label":"Pemetrexed 1000 mg/m2","type":"EXPERIMENTAL","description":"Pemetrexed 1000 mg/m2","interventionNames":["Drug: Pemetrexed 1000 mg/m2"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed 500 mg/m2","description":"500 mg/m2, intravenous (IV), every 21 days, one year from registration date","armGroupLabels":["Pemetrexed 500 mg/m2"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Pemetrexed 1000 mg/m2","description":"1000 mg/m2, intravenous (IV), every 21 days, one year from registration date","armGroupLabels":["Pemetrexed 1000 mg/m2"],"otherNames":["Alimta","LY231514"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Best Overall Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","timeFrame":"baseline to measured progressive disease (up to 3.2 years)"}],"secondaryOutcomes":[{"measure":"Duration of Response","description":"The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.","timeFrame":"time of response to progressive disease (up to 3.2 years)"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.","timeFrame":"baseline to measured progressive disease (up to 3.2 years)"},{"measure":"Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)","description":"20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.","timeFrame":"Baseline (pre-dose), 3 Months after first dose of Cycle 1"},{"measure":"Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)","description":"FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.","timeFrame":"Baseline (pre-dose), 3 Months after first dose of Cycle 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical stage III or IV\n* Previously treated with one or two chemotherapeutic regimens\n* Performance status: 0-2\n\nExclusion Criteria:\n\n\\- Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time(UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Chiba","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Ehime","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Fukuoka","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Gifu","country":"Japan","geoPoint":{"lat":35.42291,"lon":136.76039}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Gunma","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Hokkaido","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Hy≈çgo","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Kanagawa","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Kumamoto","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Miyagi","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Niigata","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Okayama","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Osaka","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Saitama","country":"Japan","geoPoint":{"lat":35.90807,"lon":139.65657}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Shizuoka","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Tokyo","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Baseline demographics and efficacy outcome measures are provided for the Full Analysis Set population (all randomized participants who met all inclusion and no exclusion criteria and received at least one dose of study drug).","groups":[{"id":"FG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"FG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"112"}]},{"type":"Safety Analysis Population","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"111"}]},{"type":"Full Analysis Set Population","achievements":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"108"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"112"}]}],"dropWithdraws":[{"type":"Entry Criteria Exclusion","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Treated with Another Systemic Agent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"21"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"72"}]},{"type":"Toxicity After Dose Reduction","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Family/Caregiver Decision","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Good Clinical Practice Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"BG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"216"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.8","spread":"8.7"},{"groupId":"BG001","value":"61.3","spread":"8.8"},{"groupId":"BG002","value":"61.1","spread":"8.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"79"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"137"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"216"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"79"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"125"}]}]},{"title":"2 - Ambulatory, No Work Activities","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Histological Types","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"157"}]}]},{"title":"Squamous Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"48"}]}]},{"title":"Large Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]}]},{"title":"Adenosquamous Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"161.0","spread":"7.9"},{"groupId":"BG001","value":"161.1","spread":"8.7"},{"groupId":"BG002","value":"161.0","spread":"8.3"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.8","spread":"9.9"},{"groupId":"BG001","value":"59.1","spread":"11.9"},{"groupId":"BG002","value":"59.5","spread":"10.9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Best Overall Response","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria as determined by the Case Judgment Committee. Best overall response was defined as the most favorable overall response recorded for each patient during the observation period. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","populationDescription":"Full analysis set: all randomized participants who met all of the inclusion criteria and none of the exclusion criteria and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline to measured progressive disease (up to 3.2 years)","groups":[{"id":"OG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"OG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"classes":[{"title":"Complete Response (CR)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Partial Response (PR)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"16"}]}]},{"title":"Stable Disease (SD)","categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"34"}]}]},{"title":"Progressive Disease (PD)","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"58"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression.","populationDescription":"Full analysis set: all randomized participants who met all of the inclusion criteria and none of the exclusion criteria and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"time of response to progressive disease (up to 3.2 years)","groups":[{"id":"OG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"OG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"3.8","upperLimit":"8.7"},{"groupId":"OG001","value":"3.0","lowerLimit":"2.8","upperLimit":"6.1"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as time from the scheduled date of the first treatment cycle until the date of confirmation of progressive disease on the overall response rating. For patients who died before confirmation of progressive disease, the number of days until the date of death (from any cause) was handled as progression-free survival.","populationDescription":"Full analysis set: all randomized participants who met all of the inclusion criteria and none of the exclusion criteria and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"baseline to measured progressive disease (up to 3.2 years)","groups":[{"id":"OG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"OG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.0","upperLimit":"3.5"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.8","upperLimit":"3.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)","description":"20-items assessed quality of life in patients undergoing chemotherapy. Scores range from 1 (not at all/very poor) to 5 (very much/very well). Face scale scores (patient circles number of the face that best fits his/her feelings) range from 1 (sad face) to 5 (smiling face). Item scores were grouped according to Functional (daily activity: 5 items), Physical (5 items), Emotional (psychological condition: 4 items), Social Attitude (5 items), and Face Scale (1 item). Score of subscales were converted to scores with range from 0 to 100. Higher scores represent higher QOL.","populationDescription":"Full analysis set: all randomized participants who met all of the inclusion criteria and none of the exclusion criteria and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (pre-dose), 3 Months after first dose of Cycle 1","groups":[{"id":"OG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"OG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"classes":[{"title":"Functional Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":"24.81"},{"groupId":"OG001","value":"75.0","spread":"26.18"}]}]},{"title":"Functional Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"23.66"},{"groupId":"OG001","value":"-3.7","spread":"19.99"}]}]},{"title":"Physical Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":"18.02"},{"groupId":"OG001","value":"73.9","spread":"21.06"}]}]},{"title":"Physical Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"18.27"},{"groupId":"OG001","value":"-3.5","spread":"17.21"}]}]},{"title":"Emotional Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":"20.21"},{"groupId":"OG001","value":"62.1","spread":"23.29"}]}]},{"title":"Emotional Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"17.36"},{"groupId":"OG001","value":"0.3","spread":"20.10"}]}]},{"title":"Sociality Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":"22.09"},{"groupId":"OG001","value":"46.1","spread":"22.37"}]}]},{"title":"Sociality Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"12.26"},{"groupId":"OG001","value":"1.6","spread":"17.05"}]}]},{"title":"Face Scale Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":"20.75"},{"groupId":"OG001","value":"59.3","spread":"25.12"}]}]},{"title":"Face Scale Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"20.64"},{"groupId":"OG001","value":"-2.1","spread":"21.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)","description":"FACT-L LCS measured health-related quality of life (HR-QL) related to additional concerns of lung cancer. Original LCS subscale scores range from 0 to 28, but the scores were converted to scores with a range of 0 to 100 in this study. Higher scores represent better HR-QL.","populationDescription":"Full analysis set: all randomized participants who met all of the inclusion criteria and none of the exclusion criteria and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline (pre-dose), 3 Months after first dose of Cycle 1","groups":[{"id":"OG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days"},{"id":"OG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"classes":[{"title":"Baseline (n=107, n=107)","categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":"18.81"},{"groupId":"OG001","value":"69.6","spread":"18.52"}]}]},{"title":"Change from Baseline (n=58, n=60)","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"16.13"},{"groupId":"OG001","value":"0.4","spread":"18.63"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed 500 mg/m2","description":"Pemetrexed 500 mg/m2, intravenous, every 21 days","seriousNumAffected":19,"seriousNumAtRisk":114,"otherNumAffected":114,"otherNumAtRisk":114},{"id":"EG001","title":"Pemetrexed 1000 mg/m2","description":"Pemetrexed 1000 mg/m2, intravenous, every 21 days","seriousNumAffected":21,"seriousNumAtRisk":111,"otherNumAffected":111,"otherNumAtRisk":111}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":111}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":111}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":111}]},{"term":"Oxygen saturation decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":111}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Neurogenic bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Apnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":111}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":111}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":111}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":111}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":111}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":28,"numAtRisk":114},{"groupId":"EG001","numEvents":31,"numAffected":21,"numAtRisk":111}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":16,"numAtRisk":114},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":111}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":187,"numAffected":64,"numAtRisk":114},{"groupId":"EG001","numEvents":133,"numAffected":64,"numAtRisk":111}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":23,"numAffected":13,"numAtRisk":111}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":33,"numAtRisk":114},{"groupId":"EG001","numEvents":54,"numAffected":36,"numAtRisk":111}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":3,"numAtRisk":111}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":111}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":18,"numAtRisk":114},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":111}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":111}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":100,"numAffected":46,"numAtRisk":114},{"groupId":"EG001","numEvents":92,"numAffected":49,"numAtRisk":111}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":111}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":111}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":35,"numAtRisk":114},{"groupId":"EG001","numEvents":97,"numAffected":49,"numAtRisk":111}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":111}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":227,"numAffected":81,"numAtRisk":114},{"groupId":"EG001","numEvents":185,"numAffected":82,"numAtRisk":111}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":271,"numAffected":88,"numAtRisk":114},{"groupId":"EG001","numEvents":254,"numAffected":88,"numAtRisk":111}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":25,"numAtRisk":114},{"groupId":"EG001","numEvents":85,"numAffected":44,"numAtRisk":111}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":35,"numAtRisk":114},{"groupId":"EG001","numEvents":64,"numAffected":35,"numAtRisk":111}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":43,"numAffected":19,"numAtRisk":111}]},{"term":"Blood chloride decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":111}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":25,"numAffected":13,"numAtRisk":111}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":22,"numAtRisk":114},{"groupId":"EG001","numEvents":42,"numAffected":19,"numAtRisk":111}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":182,"numAffected":71,"numAtRisk":114},{"groupId":"EG001","numEvents":130,"numAffected":71,"numAtRisk":111}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":18,"numAffected":6,"numAtRisk":111}]},{"term":"Blood potassium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":15,"numAffected":7,"numAtRisk":111}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":111}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":10,"numAtRisk":111}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":22,"numAffected":9,"numAtRisk":111}]},{"term":"Blood urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":20,"numAtRisk":114},{"groupId":"EG001","numEvents":27,"numAffected":13,"numAtRisk":111}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":31,"numAtRisk":114},{"groupId":"EG001","numEvents":102,"numAffected":41,"numAtRisk":111}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":111}]},{"term":"Glucose urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":21,"numAffected":8,"numAtRisk":111}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":133,"numAffected":59,"numAtRisk":114},{"groupId":"EG001","numEvents":152,"numAffected":68,"numAtRisk":111}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":109,"numAffected":56,"numAtRisk":114},{"groupId":"EG001","numEvents":163,"numAffected":64,"numAtRisk":111}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":280,"numAffected":73,"numAtRisk":114},{"groupId":"EG001","numEvents":256,"numAffected":74,"numAtRisk":111}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":22,"numAtRisk":114},{"groupId":"EG001","numEvents":84,"numAffected":37,"numAtRisk":111}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":170,"numAffected":54,"numAtRisk":114},{"groupId":"EG001","numEvents":145,"numAffected":51,"numAtRisk":111}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":15,"numAtRisk":114},{"groupId":"EG001","numEvents":43,"numAffected":12,"numAtRisk":111}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":28,"numAffected":20,"numAtRisk":111}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":18,"numAtRisk":114},{"groupId":"EG001","numEvents":27,"numAffected":16,"numAtRisk":111}]},{"term":"Red blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":109,"numAffected":46,"numAtRisk":114},{"groupId":"EG001","numEvents":82,"numAffected":45,"numAtRisk":111}]},{"term":"Urobilin urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":111}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":114},{"groupId":"EG001","numEvents":34,"numAffected":30,"numAtRisk":111}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":287,"numAffected":80,"numAtRisk":114},{"groupId":"EG001","numEvents":274,"numAffected":81,"numAtRisk":111}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":27,"numAtRisk":114},{"groupId":"EG001","numEvents":83,"numAffected":37,"numAtRisk":111}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":149,"numAffected":56,"numAtRisk":114},{"groupId":"EG001","numEvents":157,"numAffected":76,"numAtRisk":111}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":19,"numAffected":10,"numAtRisk":111}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":111}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":13,"numAffected":7,"numAtRisk":111}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":111}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":20,"numAtRisk":114},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":111}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":24,"numAffected":11,"numAtRisk":111}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":111}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":111}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":16,"numAtRisk":114},{"groupId":"EG001","numEvents":29,"numAffected":18,"numAtRisk":111}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":111}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":111}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":28,"numAtRisk":114},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":111}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":111}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":111}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":111}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":111}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":111}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":13,"numAffected":8,"numAtRisk":111}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":114},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":111}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":111}]},{"term":"Pigmentation disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":111}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":25,"numAffected":13,"numAtRisk":111}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":128,"numAffected":79,"numAtRisk":114},{"groupId":"EG001","numEvents":134,"numAffected":87,"numAtRisk":111}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":111}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}